Experimental veterinary SARS-CoV-2 vaccine cross neutralization of the Delta (B.1.617.2) variant virus in cats.

Autor: Hoyte A; Zoetis Inc., Parisppany, NJ 07054, USA. Electronic address: Ashley.hoyte@zoetis.com., Webster M; Zoetis Inc., Parisppany, NJ 07054, USA. Electronic address: mark.webster@zoetis.com., Ameiss K; Zoetis Inc., Parisppany, NJ 07054, USA. Electronic address: keith.ameiss@zoetis.com., Conlee DA; Zoetis Inc., Parisppany, NJ 07054, USA. Electronic address: douglas.conlee@zoetis.com., Hainer N; Zoetis Inc., Parisppany, NJ 07054, USA. Electronic address: Nicole.hainer@zoetis.com., Hutchinson K; Zoetis Inc., Parisppany, NJ 07054, USA. Electronic address: Kendra.hutchinson@zoetis.com., Burakova Y; Zoetis Inc., Parisppany, NJ 07054, USA. Electronic address: Yulia.burakova@zoetis.com., Dominowski PJ; Zoetis Inc., Parisppany, NJ 07054, USA. Electronic address: paul.j.dominowski@zoetis.com., Baima ET; Zoetis Inc., Parisppany, NJ 07054, USA. Electronic address: eric.t.baima@zoetis.com., King VL; Zoetis Inc., Parisppany, NJ 07054, USA. Electronic address: Vickie.l.king@zoetis.com., Rosey EL; Zoetis Inc., Parisppany, NJ 07054, USA. Electronic address: everett.rosey@zoetis.com., Hardham JM; Zoetis Inc., Parisppany, NJ 07054, USA. Electronic address: john.m.hardham@zoetis.com., Millership J; Zoetis Inc., Parisppany, NJ 07054, USA. Electronic address: jason.millership@zoetis.com., Kumar M; Zoetis Inc., Parisppany, NJ 07054, USA. Electronic address: Mahesh.kumar@zoetis.com.
Jazyk: angličtina
Zdroj: Veterinary microbiology [Vet Microbiol] 2022 May; Vol. 268, pp. 109395. Date of Electronic Publication: 2022 Mar 11.
DOI: 10.1016/j.vetmic.2022.109395
Abstrakt: SARS-CoV-2 has exhibited varying pathogenesis in a variety of Mammalia family's including Canidae, Mustelidae, Hominidae, Cervidae, Hyaenidae, and Felidae. Novel SARS-CoV-2 variants characterized by spike protein mutations have recently resulted in clinical and epidemiological concerns, as they potentially have increased infectious rates, increased transmission, or reduced neutralization by antibodies produced via vaccination. Many variants have been identified at this time, but the variant of continuing concern has been the Delta variant (B.1.617.2), due to its increased transmissibility and infectious rate. Felines vaccinated using an experimental SARS-CoV-2 spike protein-based veterinary vaccine mounted a robust immune response to the SARS-CoV-2 spike protein. Using a reporter virus particle system and feline serum, we have verified that vaccinated felines produce antibodies that neutralize the SARS-CoV-2 Wuhan strain and variant B.1.617.2 at comparable levels.
(Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: